Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Cash & Equivalents: 2014-2024

Historic Cash & Equivalents for Cartesian Therapeutics (RNAC) over the last 11 years, with Dec 2024 value amounting to $212.6 million.

  • Cartesian Therapeutics' Cash & Equivalents fell 34.59% to $143.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $143.4 million, marking a year-over-year decrease of 34.59%. This contributed to the annual value of $212.6 million for FY2024, which is 176.44% up from last year.
  • Latest data reveals that Cartesian Therapeutics reported Cash & Equivalents of $212.6 million as of FY2024, which was up 176.44% from $76.9 million recorded in FY2023.
  • Cartesian Therapeutics' Cash & Equivalents' 5-year high stood at $212.6 million during FY2024, with a 5-year trough of $76.9 million in FY2023.
  • Moreover, its 3-year median value for Cash & Equivalents was $106.4 million (2022), whereas its average is $132.0 million.
  • Per our database at Business Quant, Cartesian Therapeutics' Cash & Equivalents fell by 27.74% in 2023 and then soared by 176.44% in 2024.
  • Over the past 5 years, Cartesian Therapeutics' Cash & Equivalents (Yearly) stood at $138.7 million in 2020, then decreased by 17.76% to $114.1 million in 2021, then dropped by 6.68% to $106.4 million in 2022, then dropped by 27.74% to $76.9 million in 2023, then spiked by 176.44% to $212.6 million in 2024.